Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
39 hedge funds and large institutions have $73.9M invested in Impel Pharmaceuticals Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
8% more funds holding
Funds holding: 36 → 39 (+3)
47% less capital invested
Capital invested by funds: $141M → $73.9M (-$66.7M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$847K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$256K |
| 3 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$234K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 5 |
BlackRock
New York
|
+$74.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$860K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$76.6K |
| 3 |
Morgan Stanley
New York
|
-$31.7K |
| 4 |
E
Ergoteles
New York
|
-$30.3K |
| 5 |
Goldman Sachs
New York
|
-$23.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $50K | +$69.2K | +9,035 | +747% |
|
|
LC
27
Lindbrook Capital
Calabasas,
California
| $15K | – | – | – |
|
28
BNP Paribas Financial Markets
Paris,
France
| $6.67K | +$10.5K | +1,369 | New |
|
29
UBS Group
Zurich,
Switzerland
| $6K | – | – | – |
|
30
JP Morgan Chase
New York
| $6K | +$2.37K | +309 | +31% |
|
31
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
32
Citigroup
New York
| $2K | -$459 | -60 | -15% |
|
33
Bank of America
Charlotte,
North Carolina
| $1K | -$2.41K | -315 | -60% |
|
|
CUAMC
34
China Universal Asset Management Company
Shanghai,
China
| $1K | +$1.71K | +223 | New |
|
35
Fidelity Investments
Boston,
Massachusetts
| – | -$475 | -62 | -39% |
|
|
EI
36
Ellevest Inc
New York
| – | -$84 | -11 | -58% |
|
|
CS
37
Credit Suisse
Zurich,
Switzerland
| – | -$23 | -3 | -60% |
|
38
Wells Fargo
San Francisco,
California
| – | +$184 | +24 | +57% |
|
39
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$574 | +75 | New |
|
IMPL Hedge Fund Activity: Q3 2022 in Review
39 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q3 2022, worth a combined $73.9M — down 47% from $141M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IMPL positions and 1 closed out — a net gain of 3 holders — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Opaleye Management, adding an estimated $847K. The largest seller was Millennium Management, cutting an estimated $860K.
- 39 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q3 2022, up from 36 in Q2 2022.
- Funds reported $73.9M of Impel Pharmaceuticals Inc. Common Stock stock for Q3 2022, down 47% quarter-over-quarter.
- 4 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q3 2022 and 1 closed out, a net change of +3 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q3 2022 was Opaleye Management, an estimated $847K added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $860K sold.
Based on aggregated 13F filings for Q3 2022.